Heparin is a glycosaminoglycan with well-known anticoagulant activity. That property is used in animal models of peritoneal dialysis to maintain catheter patency and to prevent the development of peritoneal adhesions. However, heparin has a host of biologic actions beyond its role as an anticoagulant.
Heparin modulates the activity of various inflammatory cells, affects the synthesis of extracellular matrix, has antiproliferative effects on several cell types, and influences neoangiogenesis. By virtue of those actions, intraperitoneally administered heparin may interfere with peritoneal membrane homeostasis. The potential side effects of heparin use in animal models of peritoneal dialysis should be recognized to permit correct interpretation of experimental studies conducted in those models.
LindahlU., LidholtK., SpillmannD., KjellenL.More to “heparin” than anticoagulation.Thromb Res1994; 75: 1–32.
2.
SitterT., SpannaglM., SchifflH., HeldE., van HinsberghV W., KooistraT.Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.Nephrol Dial Transplant1995; 10: 677–83.
3.
HekkingL.H., AaldersM.C., Van GelderopE., ZweersM.M., StruijkD.G., HavenithC.E.Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis.Adv Perit Dial1998; 14: 14–18.
4.
ZweersM.M., SplintL.J., KredietR T., StruijkD.G.Ultra-structure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat.Nephrol Dial Transplant2001; 16: 651–4.
NelsonR.M., CecconiO., RobertsW.G., AruffoA., LinhardtR.J., BevilacquaM.P.Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation.Blood1993; 82: 3253–8.
7.
TangelderG.J., ArforsK.E.Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides.Blood1991; 77: 1565–71.
8.
WrightT.C., CastellotJ.J., DiamondJ.R., KarnovskyM.J.Regulation of cellular proliferation by heparin and heparan sulfate. In: LaneD.A., LindahlU., eds. Heparin.London: Edward Arnold;1987.
9.
JacksonR.L., BuschS.J., CardinA.D.Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes.Physiol Rev1991; 71: 481–539.
10.
CaenazzoC., GarbisaS., CeolM., BaggioB., BorsattiA., MarchiE.Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: molecular clues for its activity in nephropathy.Nephrol Dial Transplant1995; 10: 175–84.
11.
TsaiT.J., YenC.J., FangC.C., YangC.C., LeeP.H., YenT.S.Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth.Nephron1995; 71: 23–8.
12.
HommaT., BroadleyC., HooverR.L., IchokawaI., HarrisR.C.Heparin reduces the synthesis of collagenous proteins in rat glomerular mesangial cells (Abstract).Kidney Int1990; 37: 508.
13.
SnowA.D., BolenderR.P., WightT.N., ClowesA.W.Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells.Am J Pathol1990; 137: 313–30.
14.
CastellotJ.J.Jr., KambeA.M., DobsonD.E., SpiegelmanB.M.Heparin potentiation of 3T3-adipocyte stimulated angiogenesis: mechanisms of action on endothelial cells.J Cell Physiol1986; 127: 323–9.
15.
EhrlichH P., JungW.K., CostaD.E., RajaratnamJ.B.Effects of heparin on vascularization of artificial skin grafts in rats.Exp Mol Pathol1988; 48: 244–51.
16.
FolkmanJ., LangerR., LinhardtR.J., HaudenschildC., TaylorS.Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone.Science1983; 221: 719–25.
17.
HauT., SimmonsR.L.Heparin in the treatment of experimental peritonitis.Ann Surg1978; 187: 294–8.
18.
YungS., ColesG.A., WilliamsJ.D., DaviesM.The source and possible significance of hyaluronan in the peritoneal cavity.Kidney Int1994; 6: 527–33.
19.
QiaoR.L., WangH.S., YanW., OdekonL.E., Del VecchioP.J., SmithT.J.Extracellular matrix hyaluronan is a determinant of the endothelial barrier.Am J Physiol1995; 269: C103–9.
20.
BreborowiczA., WieczorowskaK., MartisL., OreopoulosD.G.Glycosaminoglycan chondroitin sulfate prevents loss of ultrafiltration during peritoneal dialysis in rats.Nephron1994; 67: 346–50.
21.
WieczorowskaK., BreborowiczA., MartisL., OreopoulosD.G.Protective effect of hyaluronic acid against peritoneal injury.Perit Dial Int1995; 15: 81–3.
22.
WuG., Wieczorowska–TobisK., PolubinskaA., KorybalskaK., FilasV., TamP.N-Acetylglucosamine changes permeability of peritoneum during chronic peritoneal dialysis in rats.Perit Dial Int1998; 18: 217–24.
23.
WangT., ChenC., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis.J Am Soc Nephrol1997; 8: 1915–20.
PolubinskaA., PawlaczykK., Kuzlan–PawlaczykM., Wieczorowska–TobisK., ChenC., MoberlyJ.B.Dialysis solution containing hyaluronan: effect on peritoneal permeability and inflammation in rats.Kidney Int2000; 57: 1182–9.
26.
PawlaczykK., Kuzlan–PawlaczykM., AnderstamB., HeimbürgerO., BergströmJ., WaniewskiJ.Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis.Nephrol Dial Transplant2001; 16: 669–71.
27.
PonceS.P., BarataJ.D., SantosJ.R.Interference of heparin with peritoneal solute transport.Nephron1985; 39: 47–9.
28.
MizuiriS., MiyataS., SakaiK., KobayashiM., MiyagiM., NakanishiT.Effect of intraperitoneal administration of heparin on advanced glycation end-products in CAPD.Perit Dial Int1999; 19: 361–5.
29.
BazzatoG., FracassoA., GambaroG., BaggioB.Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis.Lancet1995; 346: 740–1.
